Literature DB >> 29655450

Nature and Action of Antibodies in Myasthenia Gravis.

Robert L Ruff1, Robert P Lisak2.   

Abstract

This article discusses antibodies associated with immune-mediated myasthenia gravis and the pathologic action of these antibodies at the neuromuscular junctions of skeletal muscle. To explain how these antibodies act, we consider the physiology of neuromuscular transmission with emphasis on 4 features: the structure of the neuromuscular junction; the roles of postsynaptic acetylcholine receptors and voltage-gated Na+ channels and in converting the chemical signal from the nerve terminal into a propagated action potential on the muscle fiber that triggers muscle contraction; the safety factor for neuromuscular transmission; and how the safety factor is reduced in different forms of autoimmune myasthenia gravis.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acetylcholine esterases; Acetylcholine receptors; Autoantibodies; Complement; Muscle specific kinase; Neuromuscular transmission; Sodium channels

Mesh:

Substances:

Year:  2018        PMID: 29655450     DOI: 10.1016/j.ncl.2018.01.001

Source DB:  PubMed          Journal:  Neurol Clin        ISSN: 0733-8619            Impact factor:   3.806


  4 in total

1.  [Seronegative myasthenic syndrome?]

Authors:  C Selge; T Kümpfel; J Havla; F Schöberl; A Danek; P Reilich
Journal:  Nervenarzt       Date:  2020-02       Impact factor: 1.214

Review 2.  Myasthenia Gravis: Pathogenic Effects of Autoantibodies on Neuromuscular Architecture.

Authors:  Inga Koneczny; Ruth Herbst
Journal:  Cells       Date:  2019-07-02       Impact factor: 6.600

3.  Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial.

Authors:  James F Howard; Richard J Nowak; Gil I Wolfe; Miriam L Freimer; Tuan H Vu; John L Hinton; Michael Benatar; Petra W Duda; James E MacDougall; Ramin Farzaneh-Far; Henry J Kaminski; Richard Barohn; Mazen Dimachkie; Mamatha Pasnoor; Constantine Farmakidis; Tina Liu; Samantha Colgan; Michael G Benatar; Tulio Bertorini; Rekha Pillai; Robert Henegar; Mark Bromberg; Summer Gibson; Teresa Janecki; Miriam Freimer; Bakri Elsheikh; Paige Matisak; Angela Genge; Amanda Guidon; William David; Ali A Habib; Veena Mathew; Tahseen Mozaffar; John L Hinton; William Hewitt; Deborah Barnett; Patricia Sullivan; Doreen Ho; James F Howard; Rebecca E Traub; Manisha Chopra; Henry J Kaminski; Radwa Aly; Elham Bayat; Mohammad Abu-Rub; Shaida Khan; Dale Lange; Shara Holzberg; Bhupendra Khatri; Emily Lindman; Tayo Olapo; Lisa M Sershon; Robert P Lisak; Evanthia Bernitsas; Kelly Jia; Rabia Malik; Tiffany D Lewis-Collins; Michael Nicolle; Richard J Nowak; Aditi Sharma; Bhaskar Roy; Joan Nye; Michael Pulley; Alan Berger; Yasmeen Shabbir; Amit Sachdev; Kimberly Patterson; Zaeem Siddiqi; Mark Sivak; Joan Bratton; George Small; Anem Kohli; Mary Fetter; Tuan Vu; Lucy Lam; Brittany Harvey; Gil I Wolfe; Nicholas Silvestri; Kara Patrick; Karen Zakalik; Petra W Duda; James MacDougall; Ramin Farzaneh-Far; Angela Pontius; Michelle Hoarty
Journal:  JAMA Neurol       Date:  2020-05-01       Impact factor: 18.302

Review 4.  Complement in neurological disorders and emerging complement-targeted therapeutics.

Authors:  Marinos C Dalakas; Harry Alexopoulos; Peter J Spaeth
Journal:  Nat Rev Neurol       Date:  2020-10-01       Impact factor: 42.937

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.